Menu Search
Equities

Compass Pathways PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CMPSN:MEX

Compass Pathways PLC

Actions
  • Price (MXN)106.00
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change--
  • Beta1.9263
Data delayed at least 20 minutes, as of Feb 05 2026 11:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

  • Revenue in USD (TTM)0.00
  • Net income in USD-237.32m
  • Incorporated2020
  • Employees166.00
  • Location
    Compass Pathways PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
  • Phone+44 1646 905 3974
  • Websitehttps://compasspathways.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.